Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Sellers Increased By 11.09% Their Shorts As Of May 16, 2018

May 16, 2018 - By Joseph Norton

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Corporate Logo

It was recorded an increase on Anthera Pharmaceuticals Inc (NASDAQ:ANTH)’s shares shorted with 11.09%. FINRA published in May ANTH’s total 2.14M shares shorted. The up change of 11.09% from 1.92 million shares was reported. With Average volume 770,900, ANTH’s previous position will take 3 days to recover.

Ticker’s shares touched $0.3026 during the last trading session after 2.83% change.Anthera Pharmaceuticals, Inc. has volume of 270,082 shares. Since May 16, 2017 ANTH has declined 90.50% and is downtrending. ANTH underperformed the S&P500 by 102.05%.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.The firm is worth $7.08 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy.Currently it has negative earnings.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Ratings Coverage

Total analysts of 3 have positions in Anthera Pharmaceuticals (NASDAQ:ANTH) as follows: 1 rated it a “Buy”, 1 with “Sell” and 1 with “Hold”. The positive are 33%. Since January 22, 2018 according to StockzIntelligence Inc Anthera Pharmaceuticals has 5 analyst reports. On Monday, March 12 the company was downgraded by Piper Jaffray. On Tuesday, February 13 the stock of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has “Hold” rating given by Jefferies. On Tuesday, March 6 Jefferies maintained Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) with “Hold” rating. On Monday, January 22 the company was maintained by Piper Jaffray.

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.